Clinical Response to Neoadjuvant Immunotherapy Combined with Targeted Therapy and Chemotherapy in Oral Squamous Cell Carcinoma: Experience in Three Patients

Immune checkpoint inhibitors (ICIs) pembrolizumab and nivolumab have been approved for the treatment of head and neck squamous cell carcinoma (HNSCC) and used in neoadjuvant immunotherapy in clinical trials. However, combination of ICIs with targeted therapy and chemotherapy was rarely used in pre-s...

Descripción completa

Detalles Bibliográficos
Autores principales: Tian, Yu, Zhang, Lei, Jin, Nenghao, Wan, Zhiyi, Zhang, Henghui, Zhang, Haizhong
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Dove 2022
Materias:
Case Series
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9005141/
https://www.ncbi.nlm.nih.gov/pubmed/35422629
http://dx.doi.org/10.2147/OTT.S355349

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9005141/
https://www.ncbi.nlm.nih.gov/pubmed/35422629
http://dx.doi.org/10.2147/OTT.S355349

Ejemplares similares